ABOUT THE BILL
The PROTECT Rare Act (H.R. 6094) aims to improve access to treatments for rare diseases by ensuring that certain medications used to treat these conditions are covered under Medicare, Medicaid, and private health insurance plans. The bill specifically targets drugs for rare diseases or conditions that affect 200,000 or fewer individuals, conditions considered rare.
To qualify for coverage, these drugs must be supported by peer-reviewed research or medical expert recommendations and must not have been reviewed unfavorably in specified medical compendia or used in a manner that contradicts approved labels.
By establishing these criteria, the PROTECT Rare Act seeks to enhance the availability of essential treatments for rare disease patients and address gaps in coverage that can prevent them from receiving necessary care.
CURRENT SITUATION & ISSUE
Currently, many individuals with rare diseases face challenges in obtaining insurance coverage for treatments.
Despite the availability of effective medications, patients often encounter barriers such as inadequate insurance coverage, high out-of-pocket costs, and limited access to necessary drugs.
These issues can result in delays in treatment, increased health complications, and overall reduced quality of life for those affected by rare conditions.
HOW THE BILL FIXES IT
The PROTECT Rare Act addresses these challenges by mandating that Medicare, Medicaid, and private health insurance plans cover medications for rare diseases that meet specific criteria.
By requiring that these drugs be supported by credible research or medical expert opinions and ensuring that they are not used inappropriately according to their labels, the bill aims to improve coverage and access for rare disease patients.
This ensures that essential medications are available to those who need them, reduces financial barriers, and enhances overall treatment accessibility.
WHAT IT SEEKS TO DO
The PROTECT Rare Act seeks to improve insurance coverage and access for medications used to treat rare diseases by establishing clear criteria for drug coverage under Medicare, Medicaid, and private health insurance plans.
Expanded Coverage: Ensures that drugs for rare diseases affecting 200,000 or fewer individuals are covered.
Criteria for Coverage: Requires drugs to be supported by peer-reviewed research or medical expert recommendations and used according to approved labels.
Improved Access: Aims to enhance patient access to essential treatments by addressing coverage gaps.
HOW THIS LEGISLATION BENEFITS OUR COMMUNITIES
CHRONIC, COMPLEX & RARE PATIENTS
CAREGIVERS
HEALTHCARE PROFESSIONALS
RESEARCHERS
MEDICAL EDUCATORS & STUDENTS
CHRONIC, COMPLEX & RARE PATIENTS
Increased Treatment Access: Ensures that medications for rare diseases are covered by insurance, improving access to necessary treatments.
Reduced Financial Burden: Helps lower out-of-pocket costs by providing coverage for drugs that were previously hard to access.
Improved Health Outcomes: Facilitates timely access to treatments, leading to better health outcomes for rare disease patients.
CAREGIVERS
Easier Management: Simplifies the process of securing coverage for necessary medications, reducing stress on caregivers.
Financial Relief: Lessens the financial strain on caregivers by ensuring that medications are covered by insurance.
Enhanced Support: Allows caregivers to focus more on providing care rather than dealing with insurance issues.
HEALTHCARE PROFESSIONALS
Better Patient Care: Ensures that patients have access to necessary medications, improving the effectiveness of treatment plans.
Simplified Prescribing: Reduces the need for patients to navigate complex insurance issues, allowing healthcare professionals to focus on care.
Improved Outcomes: Facilitates better health outcomes through timely access to appropriate treatments.
RESEARCHERS
Increased Research Participation: Encourages more participation in clinical trials and studies by improving access to treatments.
Enhanced Data: Provides a more comprehensive understanding of treatment effectiveness due to improved patient access.
Support for Innovation: Supports ongoing research by ensuring that essential medications are covered and accessible.
MEDICAL EDUCATORS & STUDENTS


